BioMarin Pharmaceutical Inc.: BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A
European Commission Approval Expected Q3 2022 First Gene Therapy for Treatment of Hemophilia A Recommended for Approval in Europe More than 20,000 Adults with Severe, Hemophilia
Nordrhein Westfalen Hank Fuchs Johannes Oldenburg University Clinic In Bonn European Commission Biomarin Pharmaceutical Inc
Source: finanznachrichten.de